Fass Ronnie
Section of Gastroenterology, Department of Medicine, Southern Arizona VA Health Care System and University of Arizona Health Sciences Center, Tucson, Arizona 85723-0001, USA.
Curr Opin Gastroenterol. 2002 Jul;18(4):464-70. doi: 10.1097/00001574-200207000-00011.
Chest pain of esophageal origin is the most common atypical/extraesophageal manifestation of gastroesophageal reflux disease (GERD). We are increasingly recognizing the important role of the cardiologist in making the diagnosis. Studies continue to focus on the mechanisms of pain in this challenging group of patients. Factors that determine the development and persistence of visceral hypersensitivity are currently under investigation. Invasive diagnostic studies have been replaced by therapeutic trials or empirical therapies. Proton pump inhibitors have been demonstrated to be the most effective treatment for GERD-related noncardiac chest pain (NCCP). Pain modulators remain the primary therapy for non-GERD-related NCCP. Sertraline is the first selective serotonin reuptake inhibitor to demonstrate a significant improvement in chest pain symptoms.
食管源性胸痛是胃食管反流病(GERD)最常见的非典型/食管外表现。我们越来越认识到心脏病专家在做出诊断方面的重要作用。研究继续聚焦于这类具有挑战性的患者群体的疼痛机制。目前正在研究决定内脏超敏反应发生和持续的因素。侵入性诊断研究已被治疗试验或经验性治疗所取代。质子泵抑制剂已被证明是治疗GERD相关非心源性胸痛(NCCP)最有效的方法。疼痛调节剂仍然是治疗非GERD相关NCCP的主要疗法。舍曲林是第一种被证明能显著改善胸痛症状的选择性5-羟色胺再摄取抑制剂。